^
    Back
    Association details:
    Biomarker:EGFR exon 21 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

    Excerpt:
    ...Participant must have histologically or cytologically confirmed, metastatic, nonsquamous non-small cell lung cancer (NSCLC) Partipiant harboring primary epidermal growth factor receptor (EGFR) Exon 18-21 mutation and brain metastasis....
    Trial ID:
    NCT05104281
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    IASLC-WCLC 2022
    Title:

    EP13.01-002 Radiomic Signature on CT Images: A Noninvasive Biomarker for Pretreatment Discrimination of EGFR Mutations in NSCLC Patients

    Published date:
    07/12/2022
    Excerpt:
    From April 1, 2018, to January 1, 2021, a total of 31 patients with metastatic EGFR-mutant lung cancers were enrolled in this study. Osimertinib was orally administered daily (once) at a dose of 80 mg...Bevacizumab (7.5 mg/kg) was administered by drip infusion on the first day of each cycle....Of the 26 patients, 6 (23.08%) had a partial response, 20 (72.92%) had stable disease, and none had progressive disease....EGFR21 had a significantly higher risk of progression than EGFR19 (HR=6.998, 95% CI: 2.101-23.311, P=0.002).